Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors

NCT00739453 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00739453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00739453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2008
Completion date
March 3, 2012
Enrollment
95 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors